You are here: Industry Insights > Illumina

News List

FDA Authorizes First Next Generation Sequence Test for Diagnosing COVID-19 americanpharmaceuticalreview
June 22, 2020
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to Illumina, for the first COVID-19 diagnostic test utilizing next generation sequence technology.
New partnership to sequence human genomes in fight against coronavirus pharmatimes
May 13, 2020
As of this morning – Wednesday May 13 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 226,463 with 32,692 deaths.
Roche and Illumina partner to broaden patient access to genomic testing worldpharmanews
January 15, 2020
Roche has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology.
Illumina expands Genomics Accelerator to Cambridge, UK biospectrumasia
July 17, 2019
During two, six-month funding cycles per year, Illumina Accelerator provides selected startups with access to seed investment, access to Illumina sequencing systems and reagents, as well as business guidance, genomics expertise, and fully operational lab
Illumina reports financial results for first quarter of FY 2019 biospectrumasia
April 29, 2019
Research and development (R&D) expenses for the first quarter of 2019 were $169 million compared to $137 million in the prior year period.
Illumina receives 1st approval in China for its MiSeqDx sequencing system fiercebiotech
August 30, 2018
With a certificate from the China National Drug Administration, Illumina has begun encouraging more clinical laboratories to choose the MiSeqDx system to develop new clinical assays.
Illumina’s stock rides wave of high demand for genomic sequencing fiercebiotech
August 01, 2018
High demand for genomic sequencing across the biotech industry drove Illumina to record revenues this past quarter, outperforming expectations and boosting the company’s stock price by over 7% in premarket trading.